-
Shanghai Updates Biomedical R&D Import Pilot for Streamlined Customs Clearance
•
The Shanghai Municipal Commission of Commerce, in collaboration with Shanghai Customs and the Shanghai Municipal Medical Products Administration, has released an updated version of the “Shanghai Municipal Biomedical R&D Items Import Pilot.” The revised program, effective from August 1, 2023, through July 31, 2025, aims to expedite the market entry…
-
Bayer Partners with Mahana Therapeutics to Market Digital Health Technologies
•
Germany-headquartered Bayer (ETR: BAYN) has announced a strategic partnership with US digital developer Mahana Therapeutics. The collaboration focuses on the distribution and marketing of Mahana’s digital technologies, further expanding Bayer’s foray into the digital health sector. This move follows Bayer’s launch earlier this year of a precision health product development…
-
European Commission Grants Conditional Approval for Janssen’s Talvey in Multiple Myeloma
•
The European Commission (EC) has granted conditional approval to Johnson & Johnson’s (J&J; NYSE: JNJ) subsidiary, Janssen, for its innovative GPRC5D/CD3 bispecific antibody (BsAb), Talvey (talquetamab). This first-in-class treatment is designated for adults with relapsed or refractory multiple myeloma (r/rMM) who have shown disease progression after at least three prior…
-
Jiangsu Hengrui Medicine’s Fluzoparib Files for New Indication with China’s NMPA
•
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced that the National Medical Products Administration (NMPA) has accepted a new indication filing for its poly (ADP-ribose) polymerase (PARP) inhibitor, fluzoparib. The filing seeks to expand the use of fluzoparib as a maintenance therapy for patients with advanced epithelial ovarian…
-
Kintor Pharmaceutical Completes Enrollment in Phase II Study of GT20029 for Androgenetic Alopecia
•
China-based Kintor Pharmaceutical Limited (HKG: 9939) has announced the completion of patient enrollment in a Phase II clinical study for its proprietary first-in-class proteolysis targeting chimera (PROTAC) compound, GT20029. The molecule is under development as a treatment for male androgenetic alopecia (AGA), and this marks the first time a topical…
-
Novartis’s Leqvio (Inclisiran) Approved in China for Hypercholesterolemia Treatment
•
Swiss pharmaceutical giant Novartis (NYSE: NVS) has received approval from the National Medical Products Administration (NMPA) for its cholesterol-lowering drug Leqvio (inclisiran). The drug is approved for use as an adjunct treatment with diet for adult patients with primary hypercholesterolemia, including heterozygous familial and non-familial cases, or mixed type dyslipidemia.…
-
GluBio Pharmaceutical Secures $22 Million in A+ Round Financing to Advance Protein Degradation Drugs
•
GluBio Pharmaceutical Co., Ltd., an emerging player in targeted protein degradation drug development, has announced the successful completion of a $22 million A+ round financing. Since its inception in March 2021, the company has raised nearly $90 million in total funding. This latest round was led by existing investor Qiming…
-
Med Vision Secures A+ Round Financing to Accelerate Digital Therapy Commercialization
•
Hangzhou-based Med Vision Technology Co., Ltd. has successfully completed an A+ round financing, raising several tens of millions of RMB. This round was led by Hangzhou Lingxin, with existing shareholder Mifang Health Fund participating. With this financing, Med Vision has cumulatively raised over 100 million RMB in its Series A…
